Figure 2.

Overall survival. EST-3886, median follow-up 11.9 years; RTOG-85-31, median follow-up 6.5 years; Granfors 2006, follow-up 14–19 years; AST, androgen suppression therapy. (This figure should be published in the manuscript).

Kunath et al. BMC Cancer 2013 13:131   doi:10.1186/1471-2407-13-131
Download authors' original image